Johnson & Johnson is looking to buy the Swiss drugmaker Actelion in what could be a nearly $20 billion deal.
Actelion on Friday confirmed J&J’s interest, after Bloomberg first reported the potential takeover Thursday.
Shares of Actelion have jumped 16.7% to 184.40 Swiss francs ($182) since Thursday morning, giving the company a market cap of around 19.4 billion Swiss francs ($19.15 billion).
The two companies are in early talks, Bloomberg reported, and a deal may not necessarily materialise.
Business Insider Emails & Alerts
Site highlights each day to your inbox.